Form 4: Teva Pharmaceutical Executive Angus Grant Reports Share Sale to Cover Tax Obligations

EVP of Business Development at Teva Pharmaceutical Industries, Angus Grant, reports the sale of shares to cover tax withholding obligations related to vesting restricted share units.

Summary

• Angus Grant, EVP of Business Development at Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
• On August 9, 2024, Grant sold 4,065 ordinary shares at a price of $17.28 per share to cover tax withholding obligations related to the vesting of restricted share units.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 9, 2024.
• Grant also acquired 12,913 ordinary shares through the vesting of restricted share units on the same date.
• Following the reported transactions, Grant beneficially owns 8,848 ordinary shares and 38,739 restricted share units.
• The restricted share units were granted on August 9, 2023, and vest in four equal installments on August 9 of each year from 2024 to 2027.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Future Outlook

The remaining restricted share units will vest in equal installments on August 9 of each year from 2025 to 2027.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.

Key Dates